Most RA patients who switch from intravenous to subcutaneous tocilizumab are able to maintain disease control but efficacy is reduced in heavier patients, results of a phase III study shows. Patients who weighed below 70 kg maintained remission after switching, while the remission rate fell from 72.7% (8/11) to 27.3% (3/11) in patients above that weight. ...
IV to SC tocilizumab switch okay for most
9 Apr 2015